The expressions of activating NK receptors, such as NKG2D, natural cytotoxicity receptor (NCR) and DNAM-1, rebounded after successful TKI treatments for CML. Here, KLRK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.